Rafael Holdings Stock Plummets 36% After Key Drug Trial Misses Primary Endpoint

Shares of Rafael Holdings Inc. (RFL) plummeted -36.0% in afternoon trading on September 30 after the company announced disappointing top-line results from a pivotal clinical trial. The sell-off was triggered by news that a Phase 3 study for its subsidiary's lead drug candidate failed to meet its primary measure of efficacy.

Trial Misses Primary Endpoint

Cyclo Therapeutics, a subsidiary of Rafael Holdings, disclosed that its Phase 3 TransportNPC study of the drug Trappsol Cyclo did not achieve statistical significance on its primary endpoint. The trial, which evaluated the drug's effectiveness in treating Niemann-Pick Disease Type C, measured the change in a clinical severity scale at 96 weeks across the full study population of 94 patients.

According to a company press release, the result for the primary endpoint had a p-value of 0.19, well above the typical threshold of 0.05 needed to be considered statistically significant. The news immediately sent the micro-cap stock sharply lower on heavy trading volume that surged to more than 12 times its 100-day average.

Subgroup Data Shows Promise

Ad

Despite the headline failure, the company highlighted some positive findings from secondary analyses. A prespecified analysis of patients who were also receiving background therapy, representing about 83% of the study participants, did show a statistically significant result. In this subgroup, the drug demonstrated a 71% slowing of disease progression compared to a placebo.

Additionally, a survival analysis in patients with an infantile onset of the disease suggested a notable reduction in mortality risk. Based on these findings, Rafael Holdings stated it remains on track to submit a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) in the fourth quarter of 2026.

Market Impact

For investors, the failure to meet the primary endpoint in the full study population was a significant setback, as a clean win was seen as a critical de-risking event for the company's most important asset. The stock's collapse was a company-specific event, occurring while the broader U.S. stock market was trading higher. The S&P 500 gained 0.3% and the Nasdaq Composite added 0.8% on the day, buoyed by inflation data that came in cooler than expected.